rsv 276
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 4, 2017 (NCT03227029)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03916185 | Phase 1/Phase 2 (Phase 2) | May 16, 2019 | Duke University, Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03422237 | Phase 1 | Oct 4, 2017 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03227029 | Phase 1 | Aug 4, 2017 | Duke University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 2 | 2017 |
| Duke University | Academic/Hospital | 2 | 0 | 2 | 2017 |
| Johns Hopkins University | Academic/Hospital | 2 | 0 | 2 | 2017 |
3 organizations
Page 1 / 1